Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota

Angela R. Smith, Erica D. Warlick, Michelle A. Roesler, Jenny N. Poynter, Michaela Richardson, Phuong Nguyen, Adina Cioc, Betsy Hirsch, Julie A. Ross

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by dysplastic changes in the bone marrow, ineffective erythropoiesis, and an increased risk of developing acute myeloid leukemia. Treatment planning for patients with MDS is a complex process, and we sought to better characterize hematopoietic cell transplantation (HCT) outcomes and the factors that play into decision-making regarding referral of adults with MDS for definitive therapy with HCT. Patients enrolled in a population-based study of MDS between April 2010 and January 2013 who underwent HCT within the first year after enrollment were included in this analysis. Age- and risk-matched MDS patient controls also enrolled during that time period were used as a comparison. Survival was significantly better in the HCT group (48 vs. 21 %, log-rank p value 0.009). Non-HCT patients were more likely to have comorbidities, and HCT patients were more likely to have a college degree and an income >$80,000. All three of these variables were independently associated with HCT, but none impacted survival. Patients with MDS in our study who underwent HCT had better survival than a comparable group of patients who did not undergo HCT. With refined treatment techniques, more patients may be able to be considered for this therapy. More work needs to be done to determine why education and income appear to impact the decision to pursue HCT, but these factors may impact referral to an academic center where aggressive therapy like HCT is more likely to be considered.

Original languageEnglish (US)
Pages (from-to)1667-1675
Number of pages9
JournalAnnals of Hematology
Volume94
Issue number10
DOIs
StatePublished - Oct 8 2015

Fingerprint

Myelodysplastic Syndromes
Cell Transplantation
Population
Survival
Referral and Consultation
Therapeutics
Erythropoiesis
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Comorbidity
Decision Making
Bone Marrow
Education

Keywords

  • Epidemiology
  • Hematopoietic cell transplantation
  • MDS
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota. / Smith, Angela R.; Warlick, Erica D.; Roesler, Michelle A.; Poynter, Jenny N.; Richardson, Michaela; Nguyen, Phuong; Cioc, Adina; Hirsch, Betsy; Ross, Julie A.

In: Annals of Hematology, Vol. 94, No. 10, 08.10.2015, p. 1667-1675.

Research output: Contribution to journalArticle

Smith, AR, Warlick, ED, Roesler, MA, Poynter, JN, Richardson, M, Nguyen, P, Cioc, A, Hirsch, B & Ross, JA 2015, 'Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota', Annals of Hematology, vol. 94, no. 10, pp. 1667-1675. https://doi.org/10.1007/s00277-015-2422-z
Smith, Angela R. ; Warlick, Erica D. ; Roesler, Michelle A. ; Poynter, Jenny N. ; Richardson, Michaela ; Nguyen, Phuong ; Cioc, Adina ; Hirsch, Betsy ; Ross, Julie A. / Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota. In: Annals of Hematology. 2015 ; Vol. 94, No. 10. pp. 1667-1675.
@article{2e07c1156bbe45318e09e55d575ffd49,
title = "Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota",
abstract = "Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by dysplastic changes in the bone marrow, ineffective erythropoiesis, and an increased risk of developing acute myeloid leukemia. Treatment planning for patients with MDS is a complex process, and we sought to better characterize hematopoietic cell transplantation (HCT) outcomes and the factors that play into decision-making regarding referral of adults with MDS for definitive therapy with HCT. Patients enrolled in a population-based study of MDS between April 2010 and January 2013 who underwent HCT within the first year after enrollment were included in this analysis. Age- and risk-matched MDS patient controls also enrolled during that time period were used as a comparison. Survival was significantly better in the HCT group (48 vs. 21 {\%}, log-rank p value 0.009). Non-HCT patients were more likely to have comorbidities, and HCT patients were more likely to have a college degree and an income >$80,000. All three of these variables were independently associated with HCT, but none impacted survival. Patients with MDS in our study who underwent HCT had better survival than a comparable group of patients who did not undergo HCT. With refined treatment techniques, more patients may be able to be considered for this therapy. More work needs to be done to determine why education and income appear to impact the decision to pursue HCT, but these factors may impact referral to an academic center where aggressive therapy like HCT is more likely to be considered.",
keywords = "Epidemiology, Hematopoietic cell transplantation, MDS, Myelodysplastic syndrome",
author = "Smith, {Angela R.} and Warlick, {Erica D.} and Roesler, {Michelle A.} and Poynter, {Jenny N.} and Michaela Richardson and Phuong Nguyen and Adina Cioc and Betsy Hirsch and Ross, {Julie A.}",
year = "2015",
month = "10",
day = "8",
doi = "10.1007/s00277-015-2422-z",
language = "English (US)",
volume = "94",
pages = "1667--1675",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota

AU - Smith, Angela R.

AU - Warlick, Erica D.

AU - Roesler, Michelle A.

AU - Poynter, Jenny N.

AU - Richardson, Michaela

AU - Nguyen, Phuong

AU - Cioc, Adina

AU - Hirsch, Betsy

AU - Ross, Julie A.

PY - 2015/10/8

Y1 - 2015/10/8

N2 - Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by dysplastic changes in the bone marrow, ineffective erythropoiesis, and an increased risk of developing acute myeloid leukemia. Treatment planning for patients with MDS is a complex process, and we sought to better characterize hematopoietic cell transplantation (HCT) outcomes and the factors that play into decision-making regarding referral of adults with MDS for definitive therapy with HCT. Patients enrolled in a population-based study of MDS between April 2010 and January 2013 who underwent HCT within the first year after enrollment were included in this analysis. Age- and risk-matched MDS patient controls also enrolled during that time period were used as a comparison. Survival was significantly better in the HCT group (48 vs. 21 %, log-rank p value 0.009). Non-HCT patients were more likely to have comorbidities, and HCT patients were more likely to have a college degree and an income >$80,000. All three of these variables were independently associated with HCT, but none impacted survival. Patients with MDS in our study who underwent HCT had better survival than a comparable group of patients who did not undergo HCT. With refined treatment techniques, more patients may be able to be considered for this therapy. More work needs to be done to determine why education and income appear to impact the decision to pursue HCT, but these factors may impact referral to an academic center where aggressive therapy like HCT is more likely to be considered.

AB - Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by dysplastic changes in the bone marrow, ineffective erythropoiesis, and an increased risk of developing acute myeloid leukemia. Treatment planning for patients with MDS is a complex process, and we sought to better characterize hematopoietic cell transplantation (HCT) outcomes and the factors that play into decision-making regarding referral of adults with MDS for definitive therapy with HCT. Patients enrolled in a population-based study of MDS between April 2010 and January 2013 who underwent HCT within the first year after enrollment were included in this analysis. Age- and risk-matched MDS patient controls also enrolled during that time period were used as a comparison. Survival was significantly better in the HCT group (48 vs. 21 %, log-rank p value 0.009). Non-HCT patients were more likely to have comorbidities, and HCT patients were more likely to have a college degree and an income >$80,000. All three of these variables were independently associated with HCT, but none impacted survival. Patients with MDS in our study who underwent HCT had better survival than a comparable group of patients who did not undergo HCT. With refined treatment techniques, more patients may be able to be considered for this therapy. More work needs to be done to determine why education and income appear to impact the decision to pursue HCT, but these factors may impact referral to an academic center where aggressive therapy like HCT is more likely to be considered.

KW - Epidemiology

KW - Hematopoietic cell transplantation

KW - MDS

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84941025341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941025341&partnerID=8YFLogxK

U2 - 10.1007/s00277-015-2422-z

DO - 10.1007/s00277-015-2422-z

M3 - Article

C2 - 26063191

AN - SCOPUS:84941025341

VL - 94

SP - 1667

EP - 1675

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 10

ER -